Bladder cancer
New checkpoint‑inhibitor therapies are providing durable remissions for some advanced bladder cancer patients that previously had only months to live, marking a significant progress in treatment options.
Bladder cancer has historically been treated with limited options and a flat 5‑year survival rate. Recent advances, notably the introduction of checkpoint‑inhibitor drugs, have led to durable remissions in patients with advanced disease. Genomic research has identified five subtypes of bladder cancer, revealing potential vulnerabilities. The presence of bacteria in the healthy bladder offers new avenues for microbiome modulation to improve therapy. Diagnostic reliance on cystoscopy is being challenged by the development of urine‑based, less invasive tests. Risk factors include smoking, chemical exposure, and parasitic infections in certain regions. Patient experiences continue to inform care strategies.
Improved therapeutic options can extend survival and enhance quality of life for bladder cancer patients, addressing a long‑standing unmet need.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Bladder Cancer: Current Challenges and Future Directions
- Global clinical trial landscape and therapeutic trends in bladder cancer: a systematic analysis
- Adaptive Radiotherapy in Bladder Cancer: Phase II Results from the RAIDER II Trial
- The Role of Inflammation in Bladder Cancer
- ASCO GU 2026: Trastuzumab Deruxtecan in Pretreated Patients with HER2-Expressing Bladder Cancer: Final Results from the Bladder Cancer Cohort in Part 1 of DESTINY-PanTumor02